Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients

Bone Marrow Transplantation

Volumn 19, Issue 8, 1997, Pages 801-808

  Jantunen, E ^a,b   Ruutu, P ^a   Niskanen, L ^b   Volin, L ^a   Parkkali, T ^a   Koukila Kahkola P ^a   Ruutu, T ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

BMT; GVHD; Incidence; Invasive fungal infection; Risk factors

Indexed keywords

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASPERGILLUS; CANDIDA; FEMALE; FUSARIUM; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL;

EID: 0031001830     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700737     Document Type: Article

References (32)

1. Tollemar J, Ringden O, Boström L et al. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 635-641.
2. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17: 10-13.
3. Goodrich JM, Reed EC, Mori M et al. Clinical features and analysis of risk factors for invasive Candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-740.
4. Verfaillie C, Weisdorf D, Haake R et al. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8: 177-184.
5. Wingard JR, Beals SU, Santos GW et al. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant 1987; 2: 175-181.
6. McWhinney PHM, Kibbler CC, Hamon MD et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: a 13 years' experience. Clin Infect Dis 1993; 17: 397-404.
7. Morrison VA, Haake RJ, Weisdorf DJ. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994; 96: 497-503.
8. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987; 69: 369-380.
9. Atkinson K. Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 1990; 5: 209-226.
10. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. New Engl J Med 1975; 292: 895-902.
11. Schulman HM, Sullivan KM, Storb R et al. Chronic graft-versus-host disease in 52 patients. Adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-281.
12. Rhodes JC, Kwon-Chung KJ. Identification of agents of systemic mycoses. In: Evans EGV, Richardson MD (eds). Medical Mycotogy - A Practical Approach. Oxford University Press: Oxford, UK, 1989.
13. Richardson MD, Warnock DW. Fungal Infection. Diagnosis and Management. Blackwell Scientific Publications: Oxford, UK, 1993.
14. de Bock R for the EORTC Invasive Fungal Infections Cooperative Group. Epidemiology of invasive fungal infections in bone marrow transplantation. Bone Marrow Transplant 1994; 14 (Suppl. 5): S1-S2.
15. Schuler U, Ehninger G. New approaches to the prophylaxis and treatment of bacterial and fungal infections in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1994; 14 (Suppl. 4): S61-S65.
16. Momin F, Chandrasekar PH. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995; 123: 205-215.
17. Saugier-Veber P, Devergie A, Sulahian A et al. Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5 year retrospective study. Bone Marrow Transplant 1993; 12: 121-124.
18. Hoyle C, Goldman JM on the behalf of 18 UK Bone Marrow Transplant Teams. Life-threatening infections occurring more than 3 months after BMT. Bone Marrow Transplant 1994; 14: 247-252.
19. de Witte T, Zwaan F, Hermans J et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990; 74: 151-155.
20. O'Donnell MR, Schmidt GM, Tegtmeier BR et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994; 12: 827-834.
21. Ruutu T, Volin L, Elonen E et al. Triple prophylaxis with cyclosporine A (CsA), methotrexate (MTX) and methylprednisolone (MP): more effective prevention of acute GVHD than with CsA + MTX. Bone Marrow Transplant 1995; 15: 183 (Abstr. 353).
22. Guiot HFL, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994; 18: 525-532.
23. Alangaden G, Chandrasekar PH, Bailey E et al. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. Bone Marrow Transplant 1994; 14: 919-924.
24. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing marrow transplantation. New Engl J Med 1992; 326: 845-851.
25. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
26. Wingard JR, Merz WG, Rinaldi MG et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Engl J Med 1991; 326: 1274-1277.
27. Riley DK, Pavia AT, Beatty PG et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 97: 509-514.
28. Tollemar J, Ringden O, Andersson S et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577-582.
29. Ringden O, Andström E, Remberger M et al. Safety of liposomal amphotericin B (Ambisome) in 187 transplant patients treated with cyclosporin. Bone Marrow Transplant 1994; 14 (Suppl. 5): S10-S14.
30. Conneally E, Cafferkey MT, Daly PA et al. Nebulized amphotericin B as a prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990; 5: 403-406.
31. Hertenstein B, Kern WV, Schmeiser T et al. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol 1994; 68: 21-26.
32. Jeffery GM, Beard MEJ, Ikram RB et al. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991; 90: 685-692.